Test Id : KI67P
Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Automated
Useful For
Suggests clinical disorders or settings where the test may be helpful
Determining proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with carcinoid or atypical carcinoid of the lung including metastases
Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.
| Test Id | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| KIPM | Ki67 Pulmonary IHC Manual | No | No |
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Cases that are unable to be scanned for automated analysis will be changed to KIPM / Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Manual.
Method Name
A short description of the method used to perform the test
Immunohistochemistry, Automated Quantitation, Hot-Spot Technique
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
Automated, Quantitative MIB-1
Ki-67
Ki67
MIB
MIB-1
MIB1
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Cases that are unable to be scanned for automated analysis will be changed to KIPM / Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Manual.
Specimen Type
Describes the specimen type validated for testing
Special
Shipping Instructions
Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.
Necessary Information
1. Pathologist's name, address, and phone number are required.
2. Include accompanying pathology report stating the final diagnosis.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Supplies: Pathology Packaging Kit (T554)
Specimen Type:
Preferred: Formalin-fixed, paraffin-embedded tissue block containing carcinoid/atypical carcinoid tumor of the lung including metastases.
Acceptable: 2 Unstained sections containing carcinoid/atypical carcinoid tumor of the lung including metastases on charged slides cut at 4 microns <1 month ago. Tissue on the slides should have been fixed in 10% neutral buffered formalin.
Container/Tube: Pathology Packaging Kit
Collection Instructions: Submit formalin-fixed, paraffin-embedded tissue block.
Additional Information: Paraffin block will be returned with the final report.
Forms
If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Ambient (preferred) | ||
| Refrigerated | |||
Useful For
Suggests clinical disorders or settings where the test may be helpful
Determining proliferation of tumor cells in paraffin-embedded tissue blocks from patients diagnosed with carcinoid or atypical carcinoid of the lung including metastases
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Cases that are unable to be scanned for automated analysis will be changed to KIPM / Ki-67(MIB-1), Pulmonary, Quantitative Immunohistochemistry, Manual.
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Ki-67(MIB-1 clone) is a monoclonal antibody that reacts with cells undergoing DNA synthesis by binding to the Ki-67 antigen, a marker known to be expressed only in proliferating cells. By measuring the amount of tumor cells expressing Ki-67, an estimate of DNA synthesis can be determined. Studies suggest that Ki-67(MIB-1) analysis of paraffin-embedded tissue specimens may provide useful prognostic information in various tumor types.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Varies by tumor type; values reported from 0% to 100%
Interpretation
Provides information to assist in interpretation of the test results
Results will be reported as a percentage of tumor cells staining positive for Ki-67(MIB-1). Quantitative Ki-67(MIB-1) results should be interpreted within the clinical context for which the test was ordered.
The scoring method using Aiforia artificial intelligence for image analysis was developed and validated in the Biomarker and Image Analysis Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic (see Method Description).
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
The paraffin block analyzed must be representative of the patient's tumor.
Test results should be interpreted in the context of clinical findings and other laboratory data.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Boland JM, Kroneman TN, Jenkins SM, et al. Ki-67 Labeling index in pulmonary carcinoid tumors: Comparison between small biopsy and resection using tumor tracing and hot spot methods. Arch Pathol Lab Med. 2020;144(8):982-990
2. La Rosa S. Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future. Endocr Pathol. 2023;34(1):79-97. doi:10.1007/s12022-023-09755-3
Method Description
Describes how the test is performed and provides a method-specific reference
A 4-micron thick section is cut from the paraffin block. The section is stained with an immunoperoxidase method using the monoclonal antibody Ki-67 (MIB-1 clone). This is the paraffin nuclear epitope to the Ki-67 antigen. Any nucleus that has an antigen-antibody complex will cause the bright-field, brown chromogen, diaminobenzidine (DAB), to precipitate onto it. All nuclei, both DAB-positive and -negative, are counterstained with diluted hematoxylin.
Ki-67(MIB-1)-stained slides are scanned using the Leica Aperio GT450 digital scanner. The captured digital image is analyzed using a validated AI (Artificial Intelligence) algorithm by Aiforia that calculates the percentage of positive staining tumor nuclei. The Aiforia data and corresponding slide are reviewed by a pathologist for final interpretation.(Unpublished Mayo method)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
88361
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| KI67P | Ki67 Pulmonary IHC Automated | In Process |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 72132 | Interpretation | 29593-1 |
| 72133 | Participated in the Interpretation | No LOINC Needed |
| 72134 | Report electronically signed by | 19139-5 |
| 72135 | Material Received | 81178-6 |
| 72136 | Disclaimer | 62364-5 |
| 72137 | Case Number | 80398-1 |